Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras

OncoImmunology

Volumn 4, Issue 11, 2015, Pages

  Zhou, Fuling ^a,b,c   Krishnamurthy, Janani ^a,d   Wei, Yongchang ^a,b,e   Li, Ming ^a,b,d   Hunt, Kelly ^a   Johanning, Gary L ^a,b,d   Cooper, Laurence J N ^a,d   Wang Johanning, Feng ^a,b,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SRI INTERNATIONAL   (United States)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS   (United States)

^e THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

and Ras; breast cancer; chimeric antigen receptor; HERV K; metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; HUMAN ENDOGENOUS RETROVIRUS K ENVELOPE PROTEIN; INTERLEUKIN 2; K CAR; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RESAZURIN ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T CELL DEPLETION; T LYMPHOCYTE;

EID: 84941786389     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1047582     Document Type: Article

References (37)

1. G.Dotti, B.Savoldo, S.Takahashi, T.Goltsova, M.Brown, D.Rill, C.Rooney, M.Brenner. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol 2001; 29:952-61; PMID:11495701; http://dx.doi.org/10.1016/S0301-472X(01)00668-3
2. F.Mami-Chouaib, H.Echchakir, G.Dorothee, I.Vergnon, S.Chouaib. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev 2002; 188:114-21; PMID:12445285; http://dx.doi.org/10.1034/j.1600-065X.2002.18810.x
3. D.M.Davies, J.Maher. Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells. Arch Immunol Ther Exp 2010; 58:165-78; PMID:20373147; http://dx.doi.org/10.1007/s00005-010-0074-1
4. M.Sun, H.Shi, C.Liu, J.Liu, X.Liu, Y.Sun. Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res 2014; 16:R61; PMID:24919843; http://dx.doi.org/10.1186/bcr3674
5. E.Lanitis, M.Poussin, A.W.Klattenhoff, D.Song, R.Sandaltzopoulos, C.H.June, D.J.PowellJr. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 2013; 1:43-53; PMID:24409448; http://dx.doi.org/10.1158/2326-6066.CIR-13-0008
6. E.Q.Han, X.L.Li, C.R.Wang, T.F.Li, S.Y.Han. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol 2013; 6:47; PMID:23829929; http://dx.doi.org/10.1186/1756-8722-6-47
7. R.A.Morgan, J.C.Yang, M.Kitano, M.E.Dudley, C.M.Laurencot, S.A.Rosenberg. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843-51; PMID:20179677; http://dx.doi.org/10.1038/mt.2010.24
8. L.E.Kandalaft, D.J.PowellJr., G.Coukos. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 2012; 10:157; PMID:22863016; http://dx.doi.org/10.1186/1479-5876-10-157
9. C.Schlimper, A.A.Hombach, H.Abken, I.G.Schmidt-Wolf. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012; 2012:238924; PMID:22481963; http://dx.doi.org/10.1155/2012/238924
10. C.C.Kloss, M.Condomines, M.Cartellieri, M.Bachmann, M.Sadelain. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31:71-5; PMID:23242161; http://dx.doi.org/10.1038/nbt.2459
11. C.H.Lamers, S.Sleijfer, S.van Steenbergen, P.van Elzakker, B.van Krimpen, C.Groot, A.Vulto, M.den Bakker, E.Oosterwijk, R.Debets et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013; 21:904-12; PMID:23423337; http://dx.doi.org/10.1038/mt.2013.17
12. H.H.KazazianJr. Mobile elements: drivers of genome evolution. Science 2004; 303:1626-32; PMID:15016989; http://dx.doi.org/10.1126/science.1089670
13. E.S.Lander. Initial impact of the sequencing of the human genome. Nature 2011; 470:187-97; PMID:21307931; http://dx.doi.org/10.1038/nature09792
14. K.Ahn, H.S.Kim. Structural and quantitative expression analyses of HERV gene family in human tissues. Mol Cell 2009; 28:99-103; PMID:19669627; http://dx.doi.org/10.1007/s10059-009-0107-y
15. K.Reus, J.Mayer, M.Sauter, H.Zischler, N.Muller-Lantzsch, E.Meese. HERV-K(OLD): ancestor sequences of the human endogenous retrovirus family HERV-K(HML-2). J Virol 2001; 75:8917-26; PMID:11533155; http://dx.doi.org/10.1128/JVI.75.19.8917-8926.2001
16. O.Hohn, K.Hanke, N.Bannert. HERV-K(HML-2), the best preserved family of hervs: endogenization, expression, and implications in health and disease. Front Oncol 2013; 3:246; PMID:24066280; http://dx.doi.org/10.3389/fonc.2013.00246
17. R.Contreras-Galindo, M.H.Kaplan, P.Leissner, T.Verjat, I.Ferlenghi, F.Bagnoli, F.Giusti, M.H.Dosik, D.F.Hayes, S.D.Gitlin et al. Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol 2008; 82:9329-36; PMID:18632860; http://dx.doi.org/10.1128/JVI.00646-08
18. F.Wang-Johanning, A.R.Frost, B.Jian, L.Epp, D.W.Lu, G.L.Johanning. Quantitation of HERV-K env gene expression and splicing in human breast cancer. Oncogene 2003; 22:1528-35; PMID:12629516; http://dx.doi.org/10.1038/sj.onc.1206241
19. J.Zhao, K.Rycaj, S.Geng, M.Li, J.B.Plummer, B.Yin, H.Liu, X.Xu, Y.Zhang, Y.Yan et al. Expression of human endogenous retrovirus type k envelope protein is a novel candidate prognostic marker for human breast cancer. Genes Cancer 2011; 2:914-22; PMID:22593804; http://dx.doi.org/10.1177/1947601911431841
20. F.Wang-Johanning, M.Li, F.J.Esteva, K.R.Hess, B.Yin, K.Rycaj, J.B.Plummer, J.G.Garza, S.Ambs, G.L.Johanning et al. Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer. Int J Cancer 2014; 134:587-95; PMID:23873154; http://dx.doi.org/10.1002/ijc.28389
21. F.Wang-Johanning, K.Rycaj, J.B.Plummer, M.Li, B.Yin, K.Frerich, J.G.Garza, J.Shen, K.Lin, P.Yan et al. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst 2012; 104:189-210; PMID:22247020; http://dx.doi.org/10.1093/jnci/djr540
22. F.Wang-Johanning, L.Radvanyi, K.Rycaj, J.B.Plummer, P.Yan, K.J.Sastry, C.J.Piyathilake, K.K.Hunt, G.L.Johanning. Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. Cancer Res 2008; 68:5869-77; PMID:18632641; http://dx.doi.org/10.1158/0008-5472.CAN-07-6838
23. K.Rycaj, J.B.Plummer, B.Yin, M.Li, J.Garza, L.Radvanyi, Ramondetta LM, Lin K, Johanning GL, Tang DG, Wang-Johanning F et al. Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells. Clin Cancer Res 2015; 21:471-83; Epub 2014/11/06; PMID: 25370465; http://dx.doi.org/10.1158/1078-0432.ccr-14-0388
24. F.Wang-Johanning, A.R.Frost, G.L.Johanning, M.B.Khazaeli, A.F.LoBuglio, D.R.Shaw, T.V.Strong. Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. Clin Cancer Res 2001; 7:1553-60; PMID:11410490
25. S.N.Maiti, H.Huls, H.Singh, M.Dawson, M.Figliola, S.Olivares, P.Rao, Y.J.Zhao, A.Multani, G.Yang et al. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 2013; 36:112-23; PMID:23377665; http://dx.doi.org/10.1097/CJI.0b013e3182811ce9
26. H.Torikai, A.Reik, P.Q.Liu, Y.Zhou, L.Zhang, S.Maiti, H.Huls, J.C.Miller, P.Kebriaei, B.Rabinovitch et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 2012; 119:5697-705; PMID:22535661; http://dx.doi.org/10.1182/blood-2012-01-405365
27. P.Kebriaei, H.Huls, B.Jena, M.Munsell, R.Jackson, D.A.Lee, P.B.Hackett, G.Rondon, E.Shpall, R.E.Champlin et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 2012; 23:444-50; PMID:22107246; http://dx.doi.org/10.1089/hum.2011.167
28. H.Singh, P.R.Manuri, S.Olivares, N.Dara, M.J.Dawson, H.Huls, P.B.Hackett, D.B.Kohn, E.J.Shpall, R.E.Champlin et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008; 68:2961-71; PMID:18413766; http://dx.doi.org/10.1158/0008-5472.CAN-07-5600
29. S.Spranger, R.M.Spaapen, Y.Zha, J.Williams, Y.Meng, T.T.Ha, T.F.Gajewski. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
30. J.Kline, I.E.Brown, Y.Y.Zha, C.Blank, J.Strickler, H.Wouters, L.Zhang, T.F.Gajewski. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 2008; 14:3156-67; PMID:18483384; http://dx.doi.org/10.1158/1078-0432.CCR-07-4696
31. A.P.Gulati, Y.M.Yang, D.Harter, A.Mukhopadhyay, B.B.Aggarwal, D.L.Benzil, J.Whysner, A.P.Albino, R.Murali, M.Jhanwar-Uniyal. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1. Mol Carcinog 2006; 45:26-37; PMID:16267831; http://dx.doi.org/10.1002/mc.20149
32. T.Chen, Z.Meng, Y.Gan, X.Wang, F.Xu, Y.Gu, X.Xu, J.Tang, H.Zhou, X.Zhang et al. The viral oncogene Np9 acts as a critical molecular switch for co-activating beta-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells. Leukemia 2013; 27:1469-78; PMID:23307033; http://dx.doi.org/10.1038/leu.2013.8
33. G.Huang, Z.Li, X.Wan, Y.Wang, J.Dong. Human endogenous retroviral K element encodes fusogenic activity in melanoma cells. J Carcinog 2013; 12:5; PMID:23599687; http://dx.doi.org/10.4103/1477-3163.109032
34. F.Yu, J.Li, H.Chen, J.Fu, S.Ray, S.Huang, W.Ai. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 2011; 30:2161-72; PMID:21242971; http://dx.doi.org/10.1038/onc.2010.591
35. P.B.Gupta, T.T.Onder, G.Jiang, K.Tao, C.Kuperwasser, R.A.Weinberg, E.S.Lander. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645-59; PMID:19682730; http://dx.doi.org/10.1016/j.cell.2009.06.034
36. X.Yang, S.K.Sarvestani, S.Moeinzadeh, X.He, E.Jabbari. Effect of CD44 binding peptide conjugated to an engineered inert matrix on maintenance of breast cancer stem cells and tumorsphere formation. PLoS One 2013; 8:e59147; PMID:23527117; http://dx.doi.org/10.1371/journal.pone.0059147
37. K.J.Livak, T.D.Schmittgen. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262